Jay Pepose - 13 Jun 2022 Form 4 Insider Report for Ocuphire Pharma, Inc. (IRD)

Reporting relationship: Director
Issuer ticker: IRD
Reported as of: 13 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2022, 16:01:30 UTC
Prior SEC filing: 13 Apr 2022
Next SEC filing: 06 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Emily J. Johns, by Power of Attorney

Key filing fact

Jay Pepose filed Form 4 for Ocuphire Pharma, Inc. (IRD) on 15 Jun 2022.

Key facts

This page summarizes Jay Pepose's Form 4 filing for Ocuphire Pharma, Inc. (IRD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2022, 16:01.

Change

Previous filing in this sequence was filed on 13 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCUP transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 13 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $1.93
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.